Singular Highlights Key G4X™ Launch Milestones and Showcases Groundbreaking 3D Spatial Multiomic Performance at AGBT
Singular Genomics Systems announced key development milestones for its G4X™ Spatial Sequencer at the AGBT conference. The G4X Early Access Program is currently active at Beth Israel Deaconess Medical Center and Vanderbilt University Medical Center, with expansion planned for Q2. Pre-orders are open with initial shipments scheduled for June 2025.
The platform demonstrates exceptional multiomic performance in analyzing immune-oncology samples across various tissue types. Notable achievements include advanced 3D multi-omic reconstruction from 10 serial renal cell carcinoma FFPE sections, analyzing over 6.2 million cells and 438 million transcripts on a single G4X flow cell. The company also showcased its Direct-Seq technology for sequencing variable regions within cells in tissue, successfully demonstrating T- and B-cell receptor sequencing in FFPE tonsil samples.
Singular Genomics Systems ha annunciato traguardi chiave nello sviluppo del suo G4X™ Spatial Sequencer durante la conferenza AGBT. Il programma di accesso anticipato G4X è attualmente attivo presso il Beth Israel Deaconess Medical Center e il Vanderbilt University Medical Center, con un'espansione prevista per il secondo trimestre. Le prenotazioni sono aperte con le prime spedizioni programmate per giugno 2025.
La piattaforma dimostra un'eccezionale performance multiomica nell'analisi di campioni di immuno-oncologia attraverso vari tipi di tessuto. Tra i risultati notevoli ci sono la ricostruzione multiomica 3D avanzata da 10 sezioni seriali di carcinoma renale a cellule chiare FFPE, analizzando oltre 6,2 milioni di cellule e 438 milioni di trascritti su una singola cella di flusso G4X. L'azienda ha anche presentato la sua tecnologia Direct-Seq per il sequenziamento delle regioni variabili all'interno delle cellule nei tessuti, dimostrando con successo il sequenziamento dei recettori T e B nelle campioni di tonsille FFPE.
Singular Genomics Systems anunció hitos clave en el desarrollo de su G4X™ Spatial Sequencer en la conferencia AGBT. El programa de acceso anticipado G4X está actualmente activo en el Beth Israel Deaconess Medical Center y el Vanderbilt University Medical Center, con una expansión planificada para el segundo trimestre. Se aceptan pedidos anticipados con los primeros envíos programados para junio de 2025.
La plataforma demuestra un rendimiento multiómico excepcional en el análisis de muestras de inmuno-oncología en varios tipos de tejidos. Los logros notables incluyen la reconstrucción multiómica 3D avanzada a partir de 10 secciones de carcinoma renal de células claras FFPE, analizando más de 6.2 millones de células y 438 millones de transcritos en una sola celda de flujo G4X. La empresa también mostró su tecnología Direct-Seq para secuenciar regiones variables dentro de las células en tejidos, demostrando con éxito el secuenciamiento de receptores T y B en muestras de amígdalas FFPE.
Singular Genomics Systems는 AGBT 회의에서 G4X™ Spatial Sequencer의 주요 개발 이정표를 발표했습니다. G4X 조기 접근 프로그램은 현재 Beth Israel Deaconess Medical Center와 Vanderbilt University Medical Center에서 활성화되어 있으며, 2분기에 확장이 계획되어 있습니다. 사전 주문이 가능하며 초기 배송은 2025년 6월로 예정되어 있습니다.
이 플랫폼은 다양한 조직 유형에서 면역 종양 샘플을 분석하는 데 있어 뛰어난 다중 오믹 성능을 보여줍니다. 주목할 만한 성과로는 10개의 연속 신장 세포 암 FFPE 절편에서의 고급 3D 다중 오믹 재구성이 있으며, 단일 G4X 유동 세포에서 620만 개 이상의 세포와 4억 3천8백만 개의 전사체를 분석했습니다. 이 회사는 또한 조직 내 세포의 가변 영역을 시퀀싱하기 위한 Direct-Seq 기술을 선보이며, FFPE 편도 샘플에서 T세포 및 B세포 수용체 시퀀싱을 성공적으로 시연했습니다.
Singular Genomics Systems a annoncé des étapes clés de développement pour son G4X™ Spatial Sequencer lors de la conférence AGBT. Le programme d'accès anticipé G4X est actuellement actif au Beth Israel Deaconess Medical Center et au Vanderbilt University Medical Center, avec une expansion prévue pour le deuxième trimestre. Les précommandes sont ouvertes avec des expéditions initiales prévues pour juin 2025.
La plateforme démontre des performances multiomiques exceptionnelles dans l'analyse d'échantillons d'immuno-oncologie à travers divers types de tissus. Parmi les réalisations notables, on trouve une reconstruction multiomique 3D avancée à partir de 10 sections de carcinome rénal à cellules claires FFPE, analysant plus de 6,2 millions de cellules et 438 millions de transcrits sur une seule cellule de flux G4X. L'entreprise a également présenté sa technologie Direct-Seq pour le séquençage des régions variables au sein des cellules dans les tissus, démontrant avec succès le séquençage des récepteurs T et B dans des échantillons de tonsilles FFPE.
Singular Genomics Systems hat auf der AGBT-Konferenz wichtige Entwicklungsetappen für seinen G4X™ Spatial Sequencer angekündigt. Das G4X-Frühzugangsprogramm ist derzeit am Beth Israel Deaconess Medical Center und am Vanderbilt University Medical Center aktiv, mit einer geplanten Erweiterung im zweiten Quartal. Vorbestellungen sind offen, und die ersten Lieferungen sind für Juni 2025 geplant.
Die Plattform zeigt eine außergewöhnliche multiomische Leistung bei der Analyse von immunonkologischen Proben aus verschiedenen Gewebetypen. Zu den bemerkenswerten Erfolgen gehört die fortschrittliche 3D-multiomische Rekonstruktion aus 10 seriellen FFPE-Schnitten von Nierenzellkarzinom, bei der über 6,2 Millionen Zellen und 438 Millionen Transkripte auf einer einzigen G4X-Flusszelle analysiert wurden. Das Unternehmen präsentierte auch seine Direct-Seq-Technologie zum Sequenzieren variabler Regionen innerhalb von Zellen in Geweben, wobei erfolgreich das Sequenzieren von T- und B-Zellrezeptoren in FFPE-Tonsillenproben demonstriert wurde.
- Early Access Program successfully running at major medical institutions
- Pre-orders open with shipments starting June 2025
- Platform demonstrates high sensitivity, specificity, and reproducibility in FFPE samples
- Advanced 3D reconstruction capability processing 6.2M cells and 438M transcripts on single flow cell
- Successful development of Direct-Seq technology for T- and B-cell receptor sequencing
- None.
Insights
Singular Genomics' G4X™ platform represents a significant advancement in the competitive spatial multiomics market, with several key differentiators that could drive substantial market adoption. The successful early access program at Harvard Medical School and Vanderbilt University Medical Center provides important validation from top-tier research institutions.
The platform's demonstrated ability to process 6.2 million cells and 438 million transcripts on a single flow cell positions it as a highly efficient solution for large-scale studies. This throughput capability, combined with cost-efficiency, addresses a critical market need for scalable spatial biology solutions in translational research and clinical trials.
The integration of transcript, protein, and fH&E data analysis within the same sample streamlines workflow and reduces variability - a significant advantage for clinical applications. The addition of Direct-Seq technology for immune receptor sequencing expands the platform's utility in immuno-oncology research, a rapidly growing market segment.
With pre-orders opening and shipments scheduled for June 2025, the commercial rollout appears well-orchestrated. The positive feedback from early access sites regarding reproducibility and cost-efficiency suggests strong potential for market penetration, particularly in core facilities and clinical research settings where high-throughput capabilities can significantly impact operational economics.
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc., an innovator in high-throughput spatial multiomics technologies designed to advance precision medicine, today announced key development milestones for its G4X™ Spatial Sequencer at the Advances in Genome Biology and Technology (AGBT) conference in Marco Island, Florida.
G4X Early Access Program Ongoing and Broader Availability on Track
The G4X Early Access Program is currently underway at Beth Israel Deaconess Medical Center and Vanderbilt University Medical Center, providing valuable feedback highlighting the platform’s real-world potential.
“As the first early access site, we’ve had the chance to appreciate the impact of the very high throughput of the G4X, along with its ability to generate high-quality data across multiple sample types, right from the start,” said Dr. Ioannis Vlachos, Director of the Spatial Technologies Unit (www.spatialtechnology.org) at Beth Israel Deaconess Medical Center, and Associate Professor of Pathology at Harvard Medical School. “The system’s higher throughput is squarely aligned with current needs of the spatial biology field, where increased sample volumes and lower turnaround times can enable larger studies, adoption into translational or clinical trial settings, as well as higher return-of-investment and reduced costs for researchers and core facilities.”
“We’re excited to have the G4X in our lab, and the data we’ve seen so far is promising for our work with the Human Tumor Atlas Network,” said Dr. Tae Hwang, Founding Director of the Molecular Artificial Intelligence Initiatives at Vanderbilt University Medical Center. “The reproducibility, speed, and cost-efficiency allow us to scale 3D spatial analyses in larger retrospective clinical cohorts. Integrating the high-throughput spatial multimodal analysis of samples on G4X with AI can provide us critical insights into disease mechanisms and therapeutic biomarkers, ultimately advancing patient care.”
Singular plans to expand its early access program to a few more sites in Q2. Meanwhile, pre-orders for the G4X are now open, and initial shipments are on track for June 2025. Researchers wishing to start generating multiomic data can use Singular’s technology access services in the meantime.
“The G4X data we received back from Singular on our head and neck cancer sample cohort was highly informative,” remarked Dr. Shanye Yin, Assistant Professor in the Department of Pathology at Albert Einstein College of Medicine and Director of the Pathology Single-Cell Core Laboratory. “Integrating transcript, protein, and fH&E data allowed us to identify cell populations and complex tumor-immune interactions with single-cell precision. Additionally, the system's robustness is confirmed as the results are fully validated by other multi-plex imaging platforms.”
Exceptional Multiomic Performance and 3D Reconstruction Showcased
At AGBT, Singular Genomics presented data demonstrating the G4X platform’s robust integrated multiomic performance. Immune-oncology-focused lung, kidney, colon, and breast panels showed high sensitivity, specificity, and reproducibility in FFPE samples, providing comprehensive spatial insights into cancerous and healthy tissues.
Building on these data, Singular showcased advanced 3D multi-omic reconstruction and niche detection from 10 serial renal cell carcinoma FFPE sections, over 6.2 million cells, and 438 million transcripts—all from a single G4X flow cell.
“The high throughput on the G4X ensures exceptional consistency across FFPE samples, while simultaneously measuring transcripts, proteins, and fH&E within the same sample provides strong reproducibility across modalities. This unique combination makes 3D reconstruction surprisingly straightforward,” said Michael Lawson, Director, R&D at Singular Genomics. “Analyzing tissues in a higher dimension facilitates advanced spatial neighborhood analyses of immune-tumor interactions, something we believe will translate into more robust biomarker identification.”
Additional Highlights
- Direct Sequencing in Tissues: Singular advanced its proprietary Direct-Seq technology, enabling the sequencing of variable regions within cells in tissue. During AGBT, the company demonstrated accurate T- and B-cell receptor sequencing in FFPE tonsil samples.
- Data Availability: Researchers can access raw and demo datasets from Singular’s multi-tissue performance studies to explore the platform’s capabilities and validate real-world spatial data.
About Singular
Singular Genomics is a life science technology company that develops next-generation sequencing and multiomics technologies. The commercially available G4® Sequencing Platform is a powerful, highly versatile benchtop genomic sequencer designed to produce fast and accurate results. In addition, the Company is currently developing the G4X™ Spatial Sequencer, which will leverage its proprietary sequencing technology, applying it as an in situ readout for transcriptomics, proteomics and fluorescent H&E in tissue, with spatial context and on the same platform as the G4. Singular Genomics’ mission is to empower researchers and clinicians to advance science and medicine. Visit www.singulargenomics.com for more information.
Media Contact
Darius Fugere
dariusf@singulargenomics.com
FAQ
When will Singular Genomics (OMIC) begin G4X Spatial Sequencer shipments?
What is the processing capacity of OMIC's G4X Spatial Sequencer for 3D reconstruction?
Which institutions are currently testing OMIC's G4X Early Access Program?
When will OMIC expand its G4X Early Access Program?
What new technology has OMIC developed for tissue analysis?
